RNAC R&D to Revenue
Cartesian Therapeutics Inc · R&D to Revenue
RNAC R&D to Revenue
Latest reported2074.87%period ending
RNAC FY R&D/Revenue (344.93% → 2074.87%)
Latest values, visible window
High-resolution chart · PNG
RNAC r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 2,074.8659% | |
| 115.9124% | |
| 274.0348% | |
| 65.3358% | |
| 80.7927% | |
| 328.4027% | |
| 640.1528% | |
| 5,280.9524% | |
| 21,818.8406% | |
| 367.4626% | |
| 382.2991% | |
| 344.9342% |